Cargando…

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia

Treatment aim for chronic lymphocytic leukemia has been radically changed over the past years from providing only a palliative approach to reaching disease eradication and improving survival. Ofatumumab is a monoclonal humanized antibody with peculiar in vitro and in vivo properties, at present appr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frustaci, Anna Maria, Tedeschi, Alessandra, Picardi, Paola, Cairoli, Roberto, Montillo, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583123/ https://www.ncbi.nlm.nih.gov/pubmed/26425075 http://dx.doi.org/10.2147/BTT.S60503

Ejemplares similares

Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
por: Frustaci, Anna Maria, et al.
Publicado: (2023)

Role of ofatumumab in treatment of chronic lymphocytic leukemia
por: Veliz, Marays, et al.
Publicado: (2011)

Fludarabine in the treatment of chronic lymphocytic leukemia: a review
por: Ricci, Francesca, et al.
Publicado: (2009)

The spectrum of use of rituximab in chronic lymphocytic leukemia
por: Tedeschi, Alessandra, et al.
Publicado: (2010)

The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
por: Nabhan, Chadi, et al.
Publicado: (2011)

Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia
por: Ricci, Francesca, et al.
Publicado: (2011)

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab
por: Laurenti, Luca, et al.
Publicado: (2016)

Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Tuscano, Joseph, et al.
Publicado: (2020)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
por: Montillo, Marco, et al.
Publicado: (2008)

The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies
por: Castillo, Jorge, et al.
Publicado: (2010)

Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
por: AlDallal, Salma M
Publicado: (2017)

Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia
por: Castro, J E, et al.
Publicado: (2014)

Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia
por: Frustaci, Anna Maria, et al.
Publicado: (2022)

Therapeutic Experience of Progressive Multifocal Leukoencephalopathy Development during Ofatumumab Therapy for Chronic Lymphocytic Leukemia
por: Hashimoto, Yu, et al.
Publicado: (2021)

Waldenstrom’s Macroglobulinemia: An Update
por: Mazzucchelli, Maddalena, et al.
Publicado: (2018)

Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia
por: Hatswell, Anthony J., et al.
Publicado: (2017)

Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study
por: van Oers, Marinus, et al.
Publicado: (2019)

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial
por: Pettitt, Andrew R., et al.
Publicado: (2020)

Premature Ventricular Contractions and Cardiomyopathy while on Ofatumumab for Treatment of Chronic Lymphocytic Leukaemia
por: Odeyinka, Oladipo, et al.
Publicado: (2022)

A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia
por: Donnellan, William, et al.
Publicado: (2017)

High rate of minimal residual disease responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)
por: Mauro, Francesca R., et al.
Publicado: (2020)

Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial
por: Scarfò, Lydia, et al.
Publicado: (2022)

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021)

Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
por: Ogura, Michinori, et al.
Publicado: (2013)

S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME
por: Frustaci, Anna Maria, et al.
Publicado: (2023)

Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
por: Cramer, Paula, et al.
Publicado: (2020)

Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia – Time to Retire?
por: Scarfò, Lydia, et al.
Publicado: (2019)

Impfungen unter Ofatumumab gelingen
por: Facharztmagazine, Redaktion
Publicado: (2023)

Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
por: Barrientos, Jacqueline C., et al.
Publicado: (2018)

Waldenström's macroglobulinemia front line treatment
por: Tedeschi, Alessandra, et al.
Publicado: (2019)

The clinical utility of polygenic risk scores for chronic lymphocytic leukemia
por: Sud, Amit, et al.
Publicado: (2021)

Ofatumumab treatment in lupus nephritis patients
por: Haarhaus, Malena Loberg, et al.
Publicado: (2016)

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study
por: Montillo, M, et al.
Publicado: (2017)

A Nine-Gene Expression Signature Distinguished a Patient with Chronic Lymphocytic Leukemia Who Underwent Prolonged Periodic Fasting
por: Bossi, Luca Emanuele, et al.
Publicado: (2023)

B-chronic lymphocytic leukemia showed triple transformation, to diffuse large B cell, CD20-negative, and T-cell neoplasm during ofatumumab treatment: a case report
por: Imataki, Osamu, et al.
Publicado: (2018)

Healthcare Utilization and Comorbidity in Chronic Lymphocytic Leukemia
por: Rotbain, Emelie C, et al.
Publicado: (2021)

Chronic Lymphocytic Leukemia
por: Vaisitti, Tiziana, et al.
Publicado: (2020)

Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells
por: Trojani, Alessandra, et al.
Publicado: (2021)

Refractory pemphigus vulgaris successfully treated with ofatumumab
por: Klufas, Daniel M., et al.
Publicado: (2020)

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
por: Mauro, Francesca Romana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v6n1rvu4cn50boaol2sm4iu5k4